Acoramidis (BEYONTTRA®)
Acoramidis (BEYONTTRA®) and tafamidis (Vyndaqel®) are used in wild-type or variant/hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
A Managed Access Protocol (MAP) is in place for these medicines. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of acoramidis or tafamidis on the High Tech Arrangement.
Applications for reimbursement approval for these medicines will only be considered from consultants with specialist registration with the Irish Medical Council in a specialism relevant to the diagnosis and management of ATTR-CM (i.e. cardiology), who have agreed to the terms of this MAP and have been approved by the HSE (‘approved consultants’).
The approved consultant must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval or transferring reimbursement approval will only be considered from approved consultants.
A copy of the MAP for medicines for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy and the relevant application forms can be found in the Related Files section below.
For further information, please contact mmp@hse.ie .